# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## Schedule 13G

**Under the Securities Exchange Act of 1934** 

(Amendment No. \_\_\_)\*

**OMB APPROVAL** 

OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response 10.4

NeuroMetrix, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
641255104
(CUSIP Number)
September 9, 2009
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- x Rule 13d-1(c)
- Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

<sup>\*</sup>The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

#### NAMES OF REPORTING PERSONS 1.

Great Point Partners, LLC

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

37-1475292

#### CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2.

- (a)
- (b) O

#### SEC USE ONLY 3.

#### CITIZENSHIP OR PLACE OF ORGANIZATION 4.

USA

5. **SOLE VOTING POWER** NUMBER OF SHARES

0

SHARED VOTING POWER 6. BENEFICIALLY

1,651,917<sup>1</sup>

**OWNED BY EACH** 7. SOLE DISPOSITIVE POWER

0

REPORTING PERSON 8.

SHARED DISPOSITIVE POWER

1,651,917<sup>1</sup> WITH

#### AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9.

 $1.651.917^{1}$ 

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

#### 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 $7.21\%^{1, 2}$ 

#### TYPE OF REPORTING PERSON (See Instructions) 12.

Consists of 1,090,265 shares owned by Biomedical Value Fund, LP ("BVF") and 561,652 owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"). Does not include 1,035,752 shares underlying a warrant held by BVF and 533,569 shares underlying a warrant held by BOVF. The warrants are not exercisable until March 8, 2010. As a result, the reporting persons disclaim beneficial ownership of the shares underlying the warrants until 60 days prior to such date. In addition, the provisions of such warrants restrict the exercise of such warrants to the extent that, upon such exercise, the number of shares then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a group would exceed 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, sixty days prior to the warrants becoming exercisable, the reporting persons may be deemed to become the beneficial owners of such additional number of shares underlying such warrants, which together with the shares currently owned, would result in beneficial ownership by the reporting persons of such number of shares that equal to the Ownership Cap.

Based on a total of 22,907,234 shares outstanding, calculated as follows: 14,090,713 shares outstanding as reported in the Issuer's 10-Q for the quarter ended June 30, 2009, plus an additional 8,816,521 shares issued by the Issuer pursuant to a private placement as reported by the Issuer on a Form 8-K filed on September 14, 2009.

TYPE OF REPORTING PERSON (See Instructions)

12.

IN

IN

## Item 1.

(a) Name of Issuer

NeuroMetrix, Inc.

(b) Address of Issuer's Principal Executive Offices

62 Fourth Avenue, Waltham, MA 02451

## Item 2.

(a) Name of Person Filing

Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Mr. David Kroin

The Reporting Persons have entered into a Joint Filing Agreement, dated September 17, 2009, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

(b) Address of Principal Business Office, or if none, Residence

The address of the principal business office of each of the Reporting Persons is

165 Mason Street, 3rd Floor Greenwich, CT 06830

(c) Citizenship

Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

6412455104

# Item 3. If this statement is filed pursuant to §240.13d-1(b) or 240.13d.2(b) or (c), check whether the person filing is a:

Not Applicable.

- (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780)
- (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) o Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).
- (d) o Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

- (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
- (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
- (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

#### Item 4. Ownership

Biomedical Value Fund, L.P. ("BVF") is the record owner of 1,090,265 shares of Common Stock (the "BVF Shares"). Great Point Partners, LLC ("Great Point") is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. In addition, BVF is the record owner of a warrant to purchase 1,035,752 shares.

Biomedical Offshore Value Fund, Ltd. ("BOVF") is the record owner of 561,652 shares of Common Stock (the "BOVF Shares"). Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. In addition, BOVF is the record owner of a warrant to purchase 533,569 shares.

The warrants described above are not exercisable until March 8, 2010. As a result, the reporting persons disclaim beneficial ownership of the shares underlying the warrants until 60 days prior to such date. In addition, the provisions of such warrants restrict the exercise of such warrants to the extent that, upon such exercise, the number of shares then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a group would exceed 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, sixty days prior to the warrants becoming exercisable, the reporting persons may be deemed to become the beneficial owners of such additional number of shares underlying such warrants, which together with the shares currently owned, would result in beneficial ownership by the reporting persons of such number of shares that equal to the Ownership Cap.

Notwithstanding the above, Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares, the BOVF Shares and the shares underlying the warrants described above, except to the extent of their respective pecuniary interests.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

## 1. Great Point Partners, LLC

- (a) Amount beneficially owned: 1,651,917<sup>3</sup>
- (b) Percent of class: 7.21%<sup>3, 4</sup>
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote: 0 -
  - (ii) Shared power to vote or to direct the vote: 1,651,917<sup>3</sup>
  - (iii) Sole power to dispose or to direct the disposition of: 0 -.
  - (iv) Shared power to dispose or to direct the disposition of: 1,651,917<sup>3</sup>
- 2. Dr. Jeffrey R. Jay, M.D.
- (a) Amount beneficially owned: 1,651,917<sup>3</sup>
- (b) Percent of class: 7.21%<sup>3,4</sup>
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote: 0.
  - (ii) Shared power to vote or to direct the vote: 1,651,917<sup>3</sup>
  - (iii) Sole power to dispose or to direct the disposition of: 0.
  - (iv) Shared power to dispose or to direct the disposition of: 1,651,917<sup>3</sup>
- 3. Mr. David Kroin
- (a) Amount beneficially owned: 1,651,917<sup>3</sup>
- (b) Percent of class: 7.21%<sup>3,4</sup>
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote: 0.
- Consists of 1,090,265 shares owned by Biomedical Value Fund, LP ("BVF") and 561,652 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"). Does not include 1,035,752 shares underlying warrants held by BVF and 533,569 shares underlying warrants held by BOVF. The warrants are not exercisable until March 8, 2010. As a result, the reporting persons disclaim beneficial ownership of the shares underlying the warrants until 60 days prior to such date. In addition, the provisions of such warrants restrict the exercise of such warrants to the extent that, upon such exercise, the number of shares then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a group would exceed 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, sixty days prior to the warrants becoming exercisable, the reporting persons may be deemed to become the beneficial owners of such additional number of shares underlying such warrants, which together with the shares currently owned, would result in beneficial ownership by the reporting persons of such number of shares that equal to the Ownership Cap.
- Based on a total of 22,907,234 shares outstanding, calculated as follows: 14,090,713 shares outstanding as reported in the Issuer's 10-Q for the quarter ended June 30, 2009, plus an additional 8,816,521 shares issued by the Issuer pursuant to a private placement as reported by the Issuer on a Form 8-K filed on September 14, 2009.

- (ii) Shared power to vote or to direct the vote: 1,651,917<sup>3</sup>
- (iii) Sole power to dispose or to direct the disposition of: 0.
- (iv) Shared power to dispose or to direct the disposition of: 1,651,917<sup>3</sup>

## Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

## Item 6. Ownership of More than Five Percent on Behalf of Another Person:

See Item 4.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

## Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

CUSIP No. 641255104 13G Page 9 of 10 Pages

# **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 17, 2009

GREAT POINT PARTNERS, LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.

Dr. Jeffrey R. Jay, M.D., as senior managing member

/s/ Dr. Jeffrey R. Jay, M.D.

DR. JEFFREY R. JAY, M.D.

/s/ Mr. David Kroin

Mr. David Kroin

## AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree as follows:

- (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and
- (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: September 17, 2009

GREAT POINT PARTNERS, LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.

Dr. Jeffrey R. Jay, M.D., as senior managing member

/s/ Dr. Jeffrey R. Jay, M.D.

DR. JEFFREY R. JAY, M.D.

/s/ Mr. David Kroin

Mr. David Kroin